BEAM Q1 2023 Earnings — Beam Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

BEAMBeam Therapeutics Inc.

$3B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$24M+187.1% YoY

Gross Profit

-$75M-311.6% margin

Operating Income

-$99M-408.7% margin

Net Income

-$96M-398.5% margin

EPS (Diluted)

$-1.16

QoQ Revenue Growth

+20.8%

Cash Flow

Operating Cash Flow

-$110M

Free Cash Flow

-$116M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$571M

Stockholders' Equity

$762M

Cash & Equivalents

$250M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$24M	$8M	+187.1%
Gross Profit	-$75M	-$57M	-32.4%
Operating Income	-$99M	-$76M	-29.8%
Net Income	-$96M	-$69M	-39.4%